Features & Benefits
Pulse Wave Velocity
Arterial stiffness is a major cause of cardiovascular disease. Increases in arterial stiffness increase central systolic & pulse pressure, and demand on the left ventricle, and decrease the perfusion pressure through the coronary arteries, thereby increasing the risk of heart attacks, heart failure and stroke.
Pulse wave velocity is a well-established technique for obtaining a measure of arterial stiffness between two locations in the arterial tree. The velocity of the pulse wave along an artery is dependent on the stiffness of that artery.
Most commonly, pulse wave velocity is measured between the carotid and femoral peripheral artery sites in order to provide a measure of aortic stiffness. This aortic pulse wave velocity increases rapidly with age, typically doubling between the ages of 30 and 60.
The SphygmoCor Pulse Wave Velocity Vx System is sold as
an add-on to Px System, and measures the velocity of the
blood pressure waveform between any two superficial
artery sites. It uses a single-lead ECG and then a
tonometer to measure the pressure pulse waveform
sequentially in the two peripheral artery sites (eg.
carotid & femoral). When used in conjunction with the
SphygmoCor Px System, the system provides a
comprehensive assessment of the clinical significance of
the arterial stiffness measured.
-
SphygmoCor Vx is a simple-to-use "doctor’s office" Pulse Wave Velocity system, with automated software analysis and database facilities
- The pulse waveform recordings and ECG recordings are extensively evaluated to ensure consistent quality of the recordings
- Only one operator is required to use the system
SphygmoCor Vx Pulse Wave Velocity System is an add-on package to the SphygmoCor Px Non-Invasive Aortic Blood Pressure System.
-
IEC/EN 60601-1 (amendment 1 & 2) & IEC/EN 60601-1-2 (AS/NZS 3200.1.0 AS/NZS 3200.1.2) Electromedical Safety Certification (this is a mandatory requirement for medical equipment to be used in hospitals in some countries). Rating – “Type CF Class 2”
-
Device listing with the Australian Therapeutic Goods Administration (TGA)
-
CE Mark (MDD Annex II)
-
MLHW registration for Japan
-
KFDA Approval for Korea
-
Import License for China